Tamarindus indica Seed Extract-Based Botanical Compositions Alleviate Knee Pain and Improve Joint Function in Mild-to-Moderate Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Study

Objective. Knee pain and reduced joint function affect the quality of life of subjects suffering from knee osteoarthritis (KOA). The present randomized, double-blind, placebo-controlled study aimed to assess the clinical efficacy of two botanical compositions, NXT15906F6 and NXT19185, in pain relief...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2022, Vol.2022 (NA), p.2226139-14
Main Authors: Kare, Sanjeev Kumar, Vinay, Vineet, Maresz, Katarzyna, Prisk, Victor, Vik, Hogne
Format: Article
Language:English
Subjects:
Analgesics
Arthritis
Cartilage
Cartilage diseases
Cellulose
Chromatography
Clinical trials
Collagen
Cytokines
Degeneration
Double-blind studies
Ethanol
Gene expression
Inflammation
Knee
Nonsteroidal anti-inflammatory drugs
Osteoarthritis
Pain
Placebos
Quality of life
Rhizomes
Seeds
Tamarindus indica
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. Knee pain and reduced joint function affect the quality of life of subjects suffering from knee osteoarthritis (KOA). The present randomized, double-blind, placebo-controlled study aimed to assess the clinical efficacy of two botanical compositions, NXT15906F6 and NXT19185, in pain relief and improvement in the musculoskeletal function of knee osteoarthritis (KOA) subjects. NXT15906F6 contains ethanol/aqueous extract of Tamarindus indica seeds and aqueous ethanol extract of Curcuma longa rhizome, and NXT19185 is a combination of NXT15906F6 and an aqueous ethanol extract of Garcinia mangostana fruit rind. Methods. The present trial recruited ninety subjects with mild-to-moderate KOA, using a radiographic Kellgren–Lawrence (KL) grading system. The participants were randomized into one of three groups (n = 30) to receive either placebo, NXT15906F6 (250 mg/day), or NXT19185 (300 mg/day) for 56 days. The change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) score was the primary efficacy measure of the study. Improvements in the functional scores, serum proinflammatory modulators, and cartilage degradation product in the urine samples were the secondary efficacy measures. Twenty-seven subjects in each group completed the trial. Results. After the trial, NXT15906F6 and NXT19185 significantly improved P
ISSN:1741-427X
1741-4288
DOI:10.1155/2022/2226139